Company intelligence / Profile preview

Treadwell Proper Paths

San Francisco, California, USAlaurenproper.com ↗

Ownership: Private
Development stage: Other

Overview

Treadwell Therapeutics has shown promising proof-of-concept results with its PLK4 inhibitor CFI-400945 in relapsed/refractory AML, with plans for potential pivotal studies. Additional assets include a TTK/Mps1 inhibitor and an HPK1 inhibitor, both showing encouraging signals and being advanced through collaborations.

Therapeutic areas: Oncology
Modalities: Small moleculeBiologicT cell receptor engineered T cell therapy
Industry: Biotech

Partnerships

Engaged in innovative collaborative studies for some assets; specific partners not named.

Beyond the preview

Go deeper on Treadwell Proper Paths.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Treadwell Proper Paths.

Explore the full profile